key: cord-0718227-5bm3x9yi
authors: Maishan, Mazharul; Lim, Diana L.; Zimmerman, Guy A.; Matthay, Michael A.
title: A decoy mutant ACE2 designed to reduce COVID-19
date: 2022-02-28
journal: Trends Pharmacol Sci
DOI: 10.1016/j.tips.2022.02.010
sha: fa290bfe0a8d714b601704cfaf1800852a050698
doc_id: 718227
cord_uid: 5bm3x9yi

The need for new COVID-19 therapeutic strategies continues, especially as SARS-CoV-2 variants emerge. Zhang and colleagues elegantly engineered a mutant ACE2 that competitively binds SARS-CoV-2 spike protein, reduces viral uptake by human lung cells, and ameliorates SARS-CoV-2-induced lung injury in mice expressing human ACE2.

Main text (800-1000 words) currently 1057 words COVID-19 caused by SARS-CoV-2 continues to be a pandemic with a very significant health, social, and economic impact globally, including a ten-fold increase in acute respiratory failure from severe pneumonia and acute respiratory distress syndrome (ARDS) in the United States [1] . At an unprecedented pace, several effective vaccines against SARS-CoV-2 were developed, approved and deployed globally over the past year that prevent COVID-19. However, the emergence of more infectious and transmissible SARS-CoV-2 variants causing infection in vaccinated and unvaccinated individuals has prompted the testing of variant-specific vaccines. Accordingly, there is still a need for new therapeutics to combat SARS-CoV-2 infections in unvaccinated individuals as well as vaccinated individuals with breakthrough infections, especially as new variants emerge.

The SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2) on the cell surface. This enables viral entry into the cell, where it can replicate and initiate an infection. Thus, blocking the binding of the viral S protein to ACE2 on the surface of cells lining the lung airways and airspaces, in particular lung alveolar epithelial cells, is one approach to potentially prevent or attenuate SARS-CoV-2 infection and COVID-19. To this end, Zhang and colleagues[2] used deep mutagenesis to identify a mutant ACE2, referred to as sACE2.v2.4, that binds the viral S protein with 35-fold higher affinity than wild-type (WT) ACE2. They determined that higher binding affinity is in part the result of conformational stability that allows the mutant sACE2.v2.4 to exist in a form that readily binds to the viral S protein. As a result, pre-incubation with dimeric sACE2 2 .v2.4 reduced the entry of SARS-CoV-2 pseudovirus into ACE2-expressing human lung endothelial and epithelial cells in vitro.

To test sACE2 2 .v2.4 in vivo, Zhang and colleagues used transgenic mice expressing human ACE2 via the epithelial-specific K18 protomer (K18-hACE2) that were infected with live SARS-CoV- Zhang and colleagues also determined that the binding affinity of the decoy sACE2 2 .v2.4-IgG1 to S protein is comparable to that of some monoclonal antibodies targeting SARS-CoV-2 that are currently in clinical use. Both strategies aim to directly neutralize the virus by binding and preventing its docking and uptake by ACE2 on the cell surface. Monoclonal antibodies also promote viral clearance by the immune system. Intravenous infusion of sACE2 2 .v2.4-IgG1 reduced lung viral load in this study, an effect that can be attributed to the IgG1 Fc fragment as part of the fusion construct, which enables immune clearance of free virions and SARS-CoV-2-infected cells [7] . The infusion of functional human ACE2 as part of the decoy did not have a deleterious effect in lungs of K18-hACE2 mice, but it raises concern for aberrant ACE2 activity or interference with endogenous ACE2 signaling in the clinical setting. However, adverse hemodynamic changes were not observed in a human clinical trial in which wild type soluble ACE2 was administered[9], and ACE2-like enzymatic activity even ameliorated SARS-CoV-2-induced lung injury in mice and hamsters [10] . Another concern is whether a decoy could trigger an autoimmune reaction when infused into patients, which would need to be determined in early phase clinical trials.

To address the applicability of the decoy strategy to more aggressive SARS-CoV-2 variants of concern, Zhang and colleagues inoculated K18-hACE2 mice with the more transmissible and lethal P.1 variant and found that sACE2 2 .v2.4-IgG1 prevented death only when administered 12 but not 24 hours post-inoculation. This finding suggests that infection with a more lethal variant would require earlier treatment than might sometimes be possible in patients. Additionally, the investigators showed in vitro that sACE2.v2.4 binds more strongly than WT ACE2 to the S protein of several other SARS-CoV-2 variants. Nonetheless, sACE2.v2.4 was not studied here with the Omicron variant, which contains a highly mutated S protein that has the ability to escape neutralization by monoclonal antibodies that have been therapeutic against other variants that emerged previously [11] . While the Omicron S protein binds WT ACE2 more strongly than S protein of other COVID-19 variants, sACE2.v2.4 has been reported to also neutralize the Omicron variant in vitro [12] . Thus, the sACE2.v2.4 decoy strategy shows promise to remain effective against lung injury induced by Omicron and, perhaps, other variants that may yet emerge. SARS-CoV-2 in the pulmonary airways and alveolar airspaces binds wild-type (WT) human angiotensin-converting enzyme 2 (hACE2) expressed on the surface of epithelial cells to gain entry and initiate an infection, leading to lung epithelial and endothelial injury that culminates in lung edema, alveolar-capillary hyperpermeability, and mortality characterizing COVID-19 ARDS in patients. A soluble decoy ACE2 receptor mutant, sACE2 2 .v2.4-IgG1, competitively binds SARS-CoV-2 spike protein with greater affinity than WT hACE2 and prevents viral uptake by lung epithelial cells.

In K18-hACE2 mice expressing WT hACE2 on the lung epithelium and infected with SARS-CoV-2, intravenously infused sACE2 2 .v2.4-IgG1 fusion protein achieves stable concentration in the lungs and reduces lung edema and lung viral load, returns alveolar-capillary barrier permeability to a more normal level, and improves survival.

ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Engineered ACE2 counteracts vaccine-evading SARS-CoV-2 Omicron variant. bioRxiv